Abstract KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to eliminate tumor cells. In the present study. we identify two TCRs specific for the 9-mer KRAS-G12V mutant neoantigen in the context of HLA-A*11:01. https://www.ealisboa.com/special-offer-Refurbished-Nautilus-XPLOAD-Plate-Loaded-Lat-Pulldown-hot-buy/